Navigation Links
BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
Date:3/3/2011

LYNBROOK, N.Y., March 3, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011, at 1:45pm ET at the Boston Marriott Copley Place in Boston, Massachusetts.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.wsw.com/webcast/cowen3/bstc/.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its licensee Auxilium markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in Europe. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
2. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
3. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
4. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
5. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
6. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
7. BioSpecifics Technologies Corp. Stock Trading Halted Today
8. BioSpecifics Technologies Corp. To Present at BioCentury NewsMakers in the Biotech Industry Conference
9. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 11th Annual Healthcare Conference
10. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... City, Utah (PRWEB) August 27, 2014 ... that will expand its current Salt Lake City manufacturing ... underway outside of Utah to ultimately create 1,000 new ... 20 years. , “Utah is home to hardworking ... whom can be credited with Varian’s success in the ...
(Date:8/27/2014)... Aug. 27, 2014 Rhythm, a biopharmaceutical company ... deficiencies that result in metabolic disorders, announced today that ... with the U.S. Securities and Exchange Commission (SEC) relating ... its common stock. The number of shares to be ... not yet been determined. Citigroup and Cowen ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global Biodegradable Packaging ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable Packaging ... readily decomposed by the action of microorganisms. ... in terms of raw materials, production technology, ...
(Date:8/27/2014)... mysteries is how plants survive impact by the ... rays, while using this energy for photosynthesis. The ... plant,s blades quickly dissipate the energy throughout the ... at DTU Physics have now managed to successfully ... bacteria contain light-absorbing proteins which play a role ...
Breaking Biology Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7DTU researchers film protein quake for the first time 2
... Ala. , May 12 Atherotech Inc. will exhibit its ... Scientific Sessions 2010. The meeting takes place May 13-16 at ... , , ... lipid test that routinely reports directly measured LDL-C, which is included in ...
... ,, RESEARCH TRIANGLE PARK, N.C. , May 12 ... Research Clinical Trials and Statistics Unit, is running the Intergroup Exemestane Study ... women with early breast cancer and a median follow-up period of 91 ... the data from multiple centers. , ...
... Indiana Seed Fund, Indiana ,s only targeted life sciences seed ... Indianapolis -based biotechnology start-up company focused on the development of ... , , , ... 5 million Americans suffer from Alzheimer,s disease (AD), a number that ...
Cached Biology Technology:Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 2Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 3Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites 2BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 2BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 3BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 4
(Date:8/28/2014)... handful of bacterial culprits that may drive inflammatory bowel ... using patients, own intestinal immune responses as a guide. ... journal Cell . , Trillions of bacteria exist ... role in the development and progression of IBD. Yet ... species affect a person,s susceptibility to IBD and its ...
(Date:8/28/2014)... and his collaborators have developed an online analytic tool ... re-engineering cells for biomedical investigation. CellNet is a free-use ... stem cell engineering. Details of CellNet and its application ... papers in the journal Cell . , "This ... all types of cell-based investigations and can potentially offer ...
(Date:8/28/2014)... 28, 2014  Privacy Advocate and Senior Staff Attorney ... , joins the lineup of biometric and mobile commerce ... UnPlugged Executive Summit in Tampa, Florida ... announced speakers include Steven Rahman, Director, Technology and Strategy at ... Experian. The theme of this year,s event is Mobility ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2New tool aids stem cell engineering for medical research 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... clinic at the University of Michigan, neurologist Joseph Corey, M.D., ... to disease or injury. He sees the pain, ... conditions cause and wishes he could give patients more ... he heads to his research lab at the VA Ann ...
... Tom Bowman, chairman of Bowman Design Group and president ... Carbon Mitigation for Every Business" at the 2012 Behavior, ... original research and the success of own company,s green ... by 65% and decreased annual operating costs by $9000 ...
... HOUSTON (Nov. 7, 2012) Administering stem cells derived ... after a heart attack is safe but does not improve ... supported by the National Institutes of Health (NIH). ... Evaluation (TIME), mirror a previous related study, LateTIME, which found ...
Cached Biology News:Stem cells + nanofibers = Promising nerve research 2Stem cells + nanofibers = Promising nerve research 3Bone marrow stem cells do not improve short-term recovery after heart attack 2Bone marrow stem cells do not improve short-term recovery after heart attack 3
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
... Polyoxyethylene Lauryl Ether ... 0.02% Kathon Preservative. Surfactant. ... in immunohistochemistry is 1 ... 35 solution added to ...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
MMP-1/8 (H-300)...
Biology Products: